Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...
SEATTLE, WA and IRVINE, CA / ACCESSWIRE / October 5, 2023 / Küleon LLC, a private biotechnology company that has built the industry's largest library of serotonergic drugs exhibiting G protein-biased ...
This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...
Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » AM-1476 inhibits 5-HT2B receptor with preclinical antifibrotic effects ...
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence ...
The world of obesity drugs has been plagued by years of bad news, such that most potential new medications have been rejected or withdrawn due to unacceptable side-effect profiles. [1] In recent years ...
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
BOSTON (Reuters) - Two Parkinson's disease drugs cause the same kind of heart damage that led to the withdrawal of the diet drug combination "fen-phen," according to two studies published on Wednesday ...
Küleon Bioscience Awarded $2 Million NIAAA Grant to Advance a Novel, Non-Hallucinogenic 5-HT2C Therapeutic Program for Alcohol Use Disorder Küleon LLC, a preclinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback